Immune checkpoint blockade (ICB) of PD-1/PD-L1 and CTLA-4 could reinvigorate cytotoxic CD8+ T cells in the TME and dampen tumor progression in numerous types of cancers (3). The gene discussed is CD8A; the disease is cancer.